183
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Epidemiology of Aspergillosis in Cancer Patients in Taiwan

, ORCID Icon, , ORCID Icon, & ORCID Icon
Pages 3757-3766 | Published online: 13 Jul 2022

References

  • Douglas AP, Smibert OC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51(Suppl 7):143–176. doi:10.1111/imj.15591
  • Dib RW, Khalil M, Fares J, et al. Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours. J Hosp Infect. 2020;104(3):358–364. doi:10.1016/j.jhin.2019.09.020
  • Saghrouni F, Youssef YB, Gheith S, et al. Twenty-nine cases of invasive aspergillosis in neutropenic patients. Med Mal Infect. 2011;41(12):657–662. doi:10.1016/j.medmal.2011.09.011
  • Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29(5):1210–1219. doi:10.1086/313445
  • Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67(11):1567–1601. doi:10.2165/00003495-200767110-00004
  • Dandachi D, Wilson Dib R, Fernández-Cruz A, et al. Invasive pulmonary aspergillosis in patients with solid tumors: risk factors and predictors of clinical outcomes. Ann Med. 2018;50(8):713–720. doi:10.1080/07853890.2018.1518581
  • Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57. doi:10.3390/jof3040057
  • Sun K-S, Tsai C-F, Chen S-C-C, Chen -Y-Y, Huang W-C. Galactomannan testing and the incidence of invasive pulmonary aspergillosis: a 10-year Nationwide Population-Based Study in Taiwan. PLoS One. 2016;11(2):e0149964. doi:10.1371/journal.pone.0149964
  • Chiang CJ, Wang YW, Lee WC. Taiwan’s nationwide cancer registry system of 40 years: past, present, and future. J Formos Med Assoc. 2019;118(5):856–858. doi:10.1016/j.jfma.2019.01.012
  • Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45(3):291–296. doi:10.1093/jjco/hyu211
  • Huang YS, Denning DW, Shih SM, et al. Fungal diseases in Taiwan—National insurance data and estimation. J Fungi. 2019;5(3):78. doi:10.3390/jof5030078
  • Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–1505. doi:10.1016/S1470-2045(19)30456-5
  • Jenks JD, Salzer HJF, Hoenigl M. Improving the rates of Aspergillus detection: an update on current diagnostic strategies. Expert Rev Anti Infect Ther. 2019;17(1):39–50. doi:10.1080/14787210.2018.1558054
  • Kaziani K, Mitrakou E, Dimopoulos G. Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit. Ann Transl Med. 2016;4(18):352. doi:10.21037/atm.2016.08.06
  • Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38. doi:10.1016/j.cmi.2018.01.002
  • Salzer HJ, Cornely OA. Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis. Eur Respir J. 2017;49(2):1602520. doi:10.1183/13993003.02520-2016
  • Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47(1):45–68. doi:10.1183/13993003.00583-2015
  • Patterson TF, Thompson IIIGR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
  • Salzer HJF, Heyckendorf J, Kalsdorf B, Rolling T, Lange C. Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines. Mycoses. 2017;60(2):136–142. doi:10.1111/myc.12589
  • Ohmagari N, Raad II, Hachem R, Kontoyiannis DP. Invasive aspergillosis in patients with solid tumors. Cancer. 2004;101(10):2300–2302. doi:10.1002/cncr.20647
  • Sun KS, Tsai CF, Chen SC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS One. 2017;12(10):e0186422. doi:10.1371/journal.pone.0186422
  • Lowes D, Al-Shair K, Newton PJ, et al. Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J. 2017;49(2):1601062. doi:10.1183/13993003.01062-2016
  • Huang HL, Cheng MH, Lu PL, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan-a retrospective, five-year multicenter study. Sci Rep. 2017;7(1):16300. doi:10.1038/s41598-017-16559-z
  • Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376. doi:10.1093/cid/ciz1008
  • Ko BS, Chen WT, Kung HC, et al. 2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. J Microbiol Immunol Infect. 2018;51(3):287–301. doi:10.1016/j.jmii.2017.07.005